✦ LIBER ✦

Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements

✍ Scribed by Karl Broich; Marco Weiergräber; Harald Hampel

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Global regulatory requirements for xenot

✍ Luc Noel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB

Regulatory perspectives on clinical tria

✍ Toby Silverman; Paul Aebersold; Laurence Landow; Kimberly Lindsey 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 83 KB

Sham neurosurgical procedures in clinica

✍ Wendy R Galpern; Jacqueline Corrigan-Curay; Anthony E Lang; Jeffrey Kahn; Danilo 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 95 KB

Biomarkers for Alzheimer's disease: acad

✍ Hampel, Harald; Frank, Richard; Broich, Karl; Teipel, Stefan J.; Katz, Russell G 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 547 KB

Neurotrophins in neurodegenerative disea

✍ Olson, Lars 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 243 KB

Biomarkers in clinical trials of Alzheim

✍ C. Sampaio 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 45 KB